Per Johan Luthman
Head Executive VP, Research & Development Lundbeck
Seminars
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- How late stage failures continue to stem from heterogeneous patient populations and poor endpoint sensitivity, underscoring the critical need for biomarker driven stratification to boost Phase 2/3 success rates
- What 2025–2026 taught us about placebo inflation, highlighted by recent schizophrenia and depression trial outcomes, and how study site variability, digital tools, and speech/physiological biomarkers may mitigate expectation bias
- Why translational gaps persist across muscarinic, psychedelic, and neuroplasticity based mechanisms, and how emerging mechanistic and genomic biomarkers can better link target engagement with clinical effects in Phase 2/3
- How sponsors are redesigning global Phase 2/3 execution—leveraging faster moving regions, adaptive designs, and early signal-detection: to overcome long timelines, recruitment bottlenecks, and historically low CNS trial success rates
Wednesday 16th September 2026
Beyond Symptoms: Building a Biology First Framework for the Next Era of Precision Psychiatry
9:15 am
- Exploring how EEG, molecular biomarkers, and AI enabled physiological readouts can shift psychiatry from symptom clusters toward biologically grounded disease mechanisms
- Evaluating emerging immunopsychiatry insights showing how neuroinflammatory pathways and immune driven circuit changes may redefine diagnostic boundaries and treatment selection
- Assessing where psychedelic therapeutics stand today and how mechanistic understanding of neuroplasticity and receptor level signaling may open new biological targets beyond traditional symptom based categories
- Reimagining psychiatric classification by inverting the genetics to genomics pyramid—integrating genetic, epigenetic, and molecular signatures to build biology informed diagnostic frameworks
